The company's principal activity is to develop products for the treatment of cancer. The company is developing novel, small molecule therapies that target the molecular mechanisms that cause cancer. It's lead product candidate is bay 43-9006, an orally active small molecule in phase iii clinical development with bayer pharmaceuticals corporation. The company also has a small molecule cell cycle inhibitor from a collaboration with pfizer advancing towards clinical development. By exploiting the genetic differences between cancer cells and normal cells, the company is focused on changing the way cancer is treatedtm by creating anticancer therapies aimed at avoiding damage to healthy tissue while destroying malignant cells.
